AB S'JANS;SANTR NAS'ONAL' DE LJA RESHERSH S'ENTIFIK (SNRS);AB SJANS;EHNSTITJU KJURI
发明人:
GRIERSON David (FR),ГРИЕРСОН Давид (FR),BENDZhAKhAD Abdellakh (FR),БЕНДЖАХАД Абделлах (FR),MUSSI Alen (FR),МУССИ Ален (FR),KRUAZI Martin (FR),КРУАЗИ Мартин (FR),GRIERSON DAVID,BENDZHAKHAD ABDELLAKH,MUSSI ALEN,KRUAZI MARTIN
申请号：
RU2007140864/04
公开号：
RU0002445308C2
申请日:
2006.04.04
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a compound of formula I wherein the substitutes A, B, B', Q and R1-R5 in formula I are specified as follows: A and B' are one of the following groups: (i) (R6)N(CH2)n, wherein n is 0 or 1； (ii) (CH2)n, wherein n is 0, 1 or 2； (iii) C(O)(CH2)n, wherein n is 0 or 1； or provided each of A and B' represents nitrogen, together they can form a bivalent radical of formula: -(CH2)s-X1-(CH2)t- (a), wherein each s and t is independently 1 or 2, and X1 represents (CH2)n, wherein n is 0 or 1； B is one of the following groups: (i) (R6)N； (ii) oxygen； (iii) C=δ, wherein δ represents oxygen or sulphur； (iv) C(R6)=C(R7)； each R6 and R7 independently represent hydrogen, C1-4-alkyl； R1 is specified in the following groups: (i) phenyl group substituted by one or more substitute such as: - halogen specified in F, CI, Br or I, or alkyl1 group； aryl1 or heteroaryl group1； cyano, NH-alkyl1, N(alkyl1)(alkyl1) and amino； - NHCO-R or NHCOO-R, or COO-R, or CONH-R, wherein R represents hydrogen or alkyl group, or (ii) pyridinyl group which can be substituted by one substitute, such as halogen specified in I, F, Cl or Br； alkyl1 group； aryl1 group； cyano, NH-alkyl1, N(alkyl1)(alkyl1), and amino； -NHCO-R or NHCOO-R, or COO-R, or CONH-R, wherein R represents hydrogen or alkyl1 group； each R2, R3, R4 and R5 are independently specified in hydrogen or linear or branched alkyl group containing 1 to 10 carbon atoms； Q is specified in the following groups: (i) alkyl1； (ii) aryl1； (iii) heteroaryl1. The compounds of formula (I) are used for preparing a drug showing the c-kit inhibitor properties and aiming at treating a disease specified in neoplastic, allergic, inflammatory and autoimmune diseases.EFFECT: use of oxazole derivatives as tyrosine kinase inhibitors.13 cl, 1 tbl, 31 exИзобретение относится к соединению формулы I, где заместители А, В, В', Q и R1-R5 в формуле I определены следующим образом: А и В' являются одной из нижеуказанны
